MedTrace Logo

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

NCT02434666 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-09-20

No results posted yet for this study

Summary

This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).

Conditions

  • Dementia of the Alzheimer's Type

Interventions

DRUG

CPC-201

Sponsors & Collaborators

  • Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Minako Koga · Chase Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-08
Primary Completion
2016-10-18
Completion
2016-11-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02434666 on ClinicalTrials.gov